A carregar...
A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
AIMS: To evaluate the safety and efficacy of once‐weekly dulaglutide 1.5 mg, a long‐acting glucagon‐like peptide‐1 receptor agonist, compared with placebo in patients with type 2 diabetes (T2D) on glimepiride monotherapy. METHODS: This phase III, randomized (4 : 1; dulaglutide:placebo), double‐blind...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5067625/ https://ncbi.nlm.nih.gov/pubmed/26799540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12634 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|